Comparing Lorcaserin Versus Duloxetine for the Treatment of Chemotherapy-Induced Peripheral Neuropathy

Phase 2 Unknown 50 enrolled Southeastern Regional Medical Center

RandomizedParallel-groupTriple-blindTreatment

Summary

A Randomized Phase II study Comparing Lorcaserin versus Duloxetine for the Treatment of Chemotherapy-Induced Peripheral Neuropathy Produced by Oxaliplatin

Timeline

Start: 2019-06
Primary completion: 2021-02
Completion: 2021-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Duloxetine	Small molecule	60 mg	Oral
Subject	Lorcaserin	Small molecule	10 mg	Oral

Comparing Lorcaserin Versus Duloxetine for the Treatment of Chemotherapy-Induced Peripheral Neuropathy

Summary

Timeline

Drugs

Indications